Imperva Announces Second Quarter 2016 Financial Results

Imperial Capital Cuts Price Target on Imperva (IMPV) to $50 Following 2Q; Reiterates Outperform

Imperial Capital maintained an Outperform rating on Imperva (NYSE: IMPV), and cut the price target to $50.00 (from $55.00), following the company's 2Q earnings report. IMPV reported revenue of $57.9mn and adjusted net loss per share of $0.23. IMPV previously reported preliminary 2Q16 revenue of $57.5-58.0mn and adjusted... More

Wunderlich Securities Downgrades Imperva (IMPV) to Hold

Wunderlich Securities downgraded Imperva (NYSE: IMPV) from Buy to Hold.

For an analyst ratings summary and ratings history on Imperva click here. For more ratings news on Imperva click here.

Shares of Imperva closed at $45.01 yesterday.

Needham & Company Upgrades Imperva (IMPV) to Buy Amid Potential Sale; $64 PT

Needham & Company upgraded Imperva (NYSE: IMPV) from Hold to Buy with a price target of $64.00, as Qatalyst hired for a potential sale.

Analyst Scott Zeller commented, "Our IMPV downgrade post MarQ was based on our lack of confidence that IMPV could achieve... More

Imperva (IMPV) to Review Strategic Alternatives

Imperva (NYSE: IMPV) announced that its Board of Directors has initiated a comprehensive review of strategic alternatives to enhance shareholder value. The Board has retained Qatalyst Partners as financial advisor and Fenwick & West as legal advisor to assist in the process.

Impervas Board is... More

Imperva (IMPV) Misses Q2 EPS by 6c, FY Guidance Falls Short

Imperva (NYSE: IMPV) reported Q2 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $57.9 million versus the consensus estimate of $59.11 million.

GUIDANCE:

Imperva sees FY2016 EPS of ($0.82)-($0.78). Imperva sees FY2016 revenue of $248.6-250.6... More